Hojo N, Nagasaki M, Mihara Y. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report. World J Clin Cases 2022; 10(17): 5708-5716 [PMID: 35979119 DOI: 10.12998/wjcc.v10.i17.5708]
Corresponding Author of This Article
Nobumasa Hojo, MD, PhD, Chief Physician, Department of General Medicine, National Hospital Organization Hamada Medical Center, Asai-cho 777-12, Hamada City 697-8511, Shimane, Japan. hojo.nobumasa.qw@mail.hosp.go.jp
Research Domain of This Article
Hematology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 16, 2022; 10(17): 5708-5716 Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5708
Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
Nobumasa Hojo, Makoto Nagasaki, Yasuha Mihara
Nobumasa Hojo, Department of General Medicine, National Hospital Organization Hamada Medical Center, Hamada City 697-8511, Shimane, Japan
Makoto Nagasaki, Department of Pathology, National Hospital Organization Hamada Medical Center, Hamada City 697-8511, Shimane, Japan
Yasuha Mihara, Clinical Resident, National Hospital Organization Hamada Medical Center, Hamada City 697-8511, Shimane, Japan
Author contributions: Hojo N and Mihara Y were the patient’s doctors in charge, reviewed the literature and contributed to manuscript drafting; Nagasaki M was the patient’s pathologist, made the pathological diagnosis, reviewed the literature and contributed to manuscript drafting; and All authors issued final approval for this version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient for the publication of this study and any accompanying images.
Conflict-of-interest statement: The authors declare that have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nobumasa Hojo, MD, PhD, Chief Physician, Department of General Medicine, National Hospital Organization Hamada Medical Center, Asai-cho 777-12, Hamada City 697-8511, Shimane, Japan. hojo.nobumasa.qw@mail.hosp.go.jp
Received: December 11, 2021 Peer-review started: December 11, 2021 First decision: February 8, 2022 Revised: March 8, 2022 Accepted: April 3, 2022 Article in press: April 3, 2022 Published online: June 16, 2022 Processing time: 179 Days and 16 Hours
Core Tip
Core Tip: The incidence of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (BCLu-DLBCL/cHL), also known as gray zone lymphoma (GZL), is low in Asian populations. A patient presented with right-sided cervical lymph node enlargement. The patient was diagnosed based on the characteristic pathological findings, the immunophenotype [CD20+, PAX5+, OCT2+/BOB1 (focal+), CD30+, CD15-], and the strong positive expression of neoplastic programmed cell death protein ligand 1 in her lymphoma cells. There is no consensus regarding the optimal therapeutic regimen for GZL. The addition of rituximab to the chemotherapy regimen should be considered if the tumor cells are CD20+. The patient was successfully treated with the cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab regimen and has remained in complete remission for 3 years.
